<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532360</url>
  </required_header>
  <id_info>
    <org_study_id>2017-3204</org_study_id>
    <nct_id>NCT03532360</nct_id>
  </id_info>
  <brief_title>Peanut and Tree Nut Desensitization</brief_title>
  <official_title>Peanut/Tree Nut Desensitization and Induction of Tolerance in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study evaluates whether tolerance to peanuts and tree nuts can be induced in patients
      through a process of oral immunotherapy. Participants will be randomized into groups
      receiving oral immunotherapy and a control group that will receive no intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing to initiate a study assessing a common desensitization
      protocol for peanut/tree nut allergy. This study would enable the investigators to better
      determine the potential benefit of desensitization in individuals with peanut/tree nut
      allergy.

      More specifically, the investigators will address the following research objectives:

      Objectives A. To develop a protocols for peanut/tree nut desensitization with high (300mg)
      and low (30mg maintenance dose).

      B. To determine the rate of desensitization to peanut/tree nut. C. To characterize predictors
      of successful desensitization. D. To characterize molecular mechanisms involved in the
      process of desensitization

      These objectives will be evaluated through a randomized controlled trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">January 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be randomized to one of three groups: a control group that will receive no treatment, a low-dose group and a high dose group. Participants in the latter two groups will be blinded as to what group they have been assigned</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of desensitization in peanut/tree nut allergic patients as measured by blinded, placebo controlled oral food challenge</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of participants randomized to treatments arms who achieve peanut/tree nut desensitization compared to participants randomized to the control groups. This is measured by whether a participant is able to tolerate a total dose of 4172 mg crushed peanut or tree nut during an oral food challenge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of efficacy of 30 mg dose versus 300 mg dose in inducing desensitization to peanut or tree nut as measured by blinded, placebo controlled oral food challenge</measure>
    <time_frame>18 months</time_frame>
    <description>Participants in the 30 mg arm will be compared to those in the 300 mg in terms of dose tolerated at post-immunotherapy blinded, placebo-controlled oral food challenge, as well as side effects experienced during immunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of peanut or tree nut (as appropriate) specigic IgE levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of peanut or tree nut (as appropriate) specigic IgE before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of peanut or tree nut (as appropriate) specigic IgA levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of peanut or tree nut (as appropriate) specigic IgA before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of peanut or tree nut (as appropriate) specigic IgG4 levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of peanut or tree nut (as appropriate) specigic IgG4 before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of mast cell activation as measured by CD63 expression</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of mast cell activation as measured by CD63 expression before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of of DNA methylation levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of DNA methylation levels before, during and after the desensitization process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over the immunotherapy process of Regulatory T cell levels</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of Regulatory T cell levels, before, during and after the desensitization process</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peanut Allergy</condition>
  <condition>Tree Nut Allergy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral immunotherapy</intervention_name>
    <description>Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic</description>
    <arm_group_label>Low-dose</arm_group_label>
    <arm_group_label>High-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Children 6 years and older who satisfy all the following criteria will
        be included:

          -  A history suggestive of immediate allergy to peanut/tree nut . A convincing clinical
             history of an IgE mediated reaction to a specific food will be defined as a minimum of
             2 mild signs/symptoms or 1 moderate or 1 severe sign/symptom that was likely IgE
             mediated and occurred within 120 minutes after ingestion or contact (or inhalation in
             the case of fish and shellfish). Reactions will be considered mild if they involve
             pruritus, urticaria, flushing, or rhinoconjunctivitis; moderate if they involve
             angioedema, throat tightness, gastrointestinal complaints, or breathing difficulties
             (other than wheeze); and severe if they involve wheeze, cyanosis, or circulatory
             collapse.(54-57)

          -  The presence of at least one of the following confirmatory tests:

               -  Positive SPT to peanut/tree nut or its proteins (weal diameter 3 mm larger than
                  that of the normal saline control). The allergens used will be commercial
                  extracts of peanut/tree nut (Omega Labs, Toronto, Ontario).

               -  Detection of serum specific IgE (&gt;0.35 kU/L) to peanut/tree nut or any of its
                  proteins, measured by fluorescence enzyme immunoassay (Phadia, CAP System,
                  Uppsala, Sweden).

               -  Positive oral challenge test to peanut/tree nut. Oral challenges will be
                  performed with raw peanut/tree nut according to the recommendations of the
                  position paper of the European Academy of Allergology and Clinical Immunology
                  (58).

          -  Informed consent form signed by the parents or legal guardian

        Exclusion criteria.

          -  Patients who are unstable from a respiratory point of view ..

          -  Patients who present with intercurrent disease at the time of starting
             desensitization.

          -  Non-IgE-mediated or non-immunological adverse reactions to nuts.

          -  Malignant or immunopathological diseases and/or severe primary or secondary immune
             deficiencies.

          -  Patients receiving immunosuppressor therapy

          -  Patients receiving Î²-blockers (including topical formulations).

          -  Associated diseases contraindicating the use of epinephrine: cardiovascular disease or
             severe hypertension.

          -  Patients diagnosed with eosinophilic gastrointestinal disorder .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Duncan Lejtenyi, MSc</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>22369</phone_ext>
    <email>duncan.lejtenyi@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Lee</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>67096</phone_ext>
    <email>jennifer.lee@muhc.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Lejtenyi, MSc</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>22369</phone_ext>
      <email>duncan.lejtenyi@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Lee</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>67096</phone_ext>
      <email>jennifer.lee@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Moshe Ben-Shoshan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Bruce Mazer</investigator_full_name>
    <investigator_title>Executive Director and CSO (Interim)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
    <mesh_term>Nut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

